Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,948 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Early treatment intensification with R-ICE and 90Y-ibritumomab tiuxetan (Zevalin)-BEAM stem cell transplantation in patients with high-risk diffuse large B-cell lymphoma patients and positive interim PET after 4 cycles of R-CHOP-14.
Hertzberg M, Gandhi MK, Trotman J, Butcher B, Taper J, Johnston A, Gill D, Ho SJ, Cull G, Fay K, Chong G, Grigg A, Lewis ID, Milliken S, Renwick W, Hahn U, Filshie R, Kannourakis G, Watson AM, Warburton P, Wirth A, Seymour JF, Hofman MS, Hicks RJ; Australasian Leukaemia Lymphoma Group (ALLG). Hertzberg M, et al. Among authors: gill d. Haematologica. 2017 Feb;102(2):356-363. doi: 10.3324/haematol.2016.154039. Epub 2016 Nov 10. Haematologica. 2017. PMID: 28143954 Free PMC article. Clinical Trial.
Ratios of T-cell immune effectors and checkpoint molecules as prognostic biomarkers in diffuse large B-cell lymphoma: a population-based study.
Keane C, Vari F, Hertzberg M, Cao KA, Green MR, Han E, Seymour JF, Hicks RJ, Gill D, Crooks P, Gould C, Jones K, Griffiths LR, Talaulikar D, Jain S, Tobin J, Gandhi MK. Keane C, et al. Among authors: gill d. Lancet Haematol. 2015 Oct;2(10):e445-55. doi: 10.1016/S2352-3026(15)00150-7. Epub 2015 Oct 1. Lancet Haematol. 2015. PMID: 26686046 Clinical Trial.
Idarubicin Dose Escalation During Consolidation Therapy for Adult Acute Myeloid Leukemia.
Bradstock KF, Link E, Di Iulio J, Szer J, Marlton P, Wei AH, Enno A, Schwarer A, Lewis ID, D'Rozario J, Coyle L, Cull G, Campbell P, Leahy MF, Hahn U, Cannell P, Tiley C, Lowenthal RM, Moore J, Cartwright K, Cunningham I, Taper J, Grigg A, Roberts AW, Benson W, Hertzberg M, Deveridge S, Rowlings P, Mills AK, Gill D, Bardy P, Campbell L, Seymour JF; Australasian Leukaemia & Lymphoma Group. Bradstock KF, et al. Among authors: d rozario j, gill d. J Clin Oncol. 2017 May 20;35(15):1678-1685. doi: 10.1200/JCO.2016.70.6374. Epub 2017 Apr 3. J Clin Oncol. 2017. PMID: 28368672 Clinical Trial.
Results of the APML3 trial incorporating all-trans-retinoic acid and idarubicin in both induction and consolidation as initial therapy for patients with acute promyelocytic leukemia.
Iland H, Bradstock K, Seymour J, Hertzberg M, Grigg A, Taylor K, Catalano J, Cannell P, Horvath N, Deveridge S, Browett P, Brighton T, Chong L, Springall F, Ayling J, Catalano A, Supple S, Collins M, Di Iulio J, Reynolds J; Australasian Leukaemia and Lymphoma Group. Iland H, et al. Haematologica. 2012 Feb;97(2):227-34. doi: 10.3324/haematol.2011.047506. Epub 2011 Oct 11. Haematologica. 2012. PMID: 21993673 Free PMC article. Clinical Trial.
Safety and efficacy of pegfilgrastim compared to granulocyte colony stimulating factor (G-CSF) supporting a dose-intensive, rapidly cycling anti-metabolite containing chemotherapy regimen (Hyper-CVAD) for lymphoid malignancy.
Lane SW, Crawford J, Kenealy M, Cull G, Seymour JF, Prince HM, Marlton P, Gill D, Mollee PN. Lane SW, et al. Among authors: gill d. Leuk Lymphoma. 2006 Sep;47(9):1813-7. doi: 10.1080/10428190600632832. Leuk Lymphoma. 2006. PMID: 17064993
Phase II study of autologous stem cell transplant using busulfan-melphalan chemotherapy-only conditioning followed by interferon for relapsed poor prognosis follicular non-Hodgkin lymphoma.
Grigg AP, Stone J, Milner AD, Schwarer AP, Wolf M, Prince HM, Seymour J, Gill D, Ellis D, Bashford J; Australasian Leukaemia & Lymphoma Group. Grigg AP, et al. Among authors: gill d. Leuk Lymphoma. 2010 Apr;51(4):641-9. doi: 10.3109/10428191003611428. Leuk Lymphoma. 2010. PMID: 20218809 Clinical Trial.
Cladribine prolongs progression-free survival and time to second treatment compared to fludarabine and high-dose chlorambucil in chronic lymphocytic leukemia.
Mulligan SP, Karlsson K, Strömberg M, Jønsson V, Gill D, Hammerström J, Hertzberg M, McLennan R, Uggla B, Norman J, Wallvik J, Sundström G, Johansson H, Brandberg Y, Liliemark J, Juliusson G; Scandinavian and Australasian Leukaemia Lymphoma Groups (Allg). Mulligan SP, et al. Among authors: gill d. Leuk Lymphoma. 2014 Dec;55(12):2769-77. doi: 10.3109/10428194.2014.893306. Epub 2014 Apr 16. Leuk Lymphoma. 2014. PMID: 24524339 Clinical Trial.
Plasma Epstein-Barr virus (EBV) DNA is a biomarker for EBV-positive Hodgkin's lymphoma.
Gandhi MK, Lambley E, Burrows J, Dua U, Elliott S, Shaw PJ, Prince HM, Wolf M, Clarke K, Underhill C, Mills T, Mollee P, Gill D, Marlton P, Seymour JF, Khanna R. Gandhi MK, et al. Among authors: gill d. Clin Cancer Res. 2006 Jan 15;12(2):460-4. doi: 10.1158/1078-0432.CCR-05-2008. Clin Cancer Res. 2006. PMID: 16428487
Epstein-Barr virus T-cell immunity despite rituximab.
Nehring AK, Dua U, Mollee P, Gill D, Grimmett K, Khanna R, Moss D, Gandhi MK. Nehring AK, et al. Among authors: gill d. Br J Haematol. 2007 Feb;136(4):628-32. doi: 10.1111/j.1365-2141.2006.06482.x. Br J Haematol. 2007. PMID: 17223914 Free article. Clinical Trial.
Improvement in Parameters of Hematologic and Immunologic Function and Patient Well-being in the Phase III RESONATE Study of Ibrutinib Versus Ofatumumab in Patients With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma.
Barrientos JC, O'Brien S, Brown JR, Kay NE, Reddy NM, Coutre S, Tam C, Mulligan S, Jaeger U, Devereux S, Pocock C, Robak T, Schuster SJ, Schuh A, Gill D, Bloor A, Dearden C, Moreno C, Cull G, Hamblin M, Jones JA, Eckert K, Solman IG, Suzuki S, Hsu E, James DF, Byrd JC, Hillmen P. Barrientos JC, et al. Among authors: gill d. Clin Lymphoma Myeloma Leuk. 2018 Dec;18(12):803-813.e7. doi: 10.1016/j.clml.2018.08.007. Epub 2018 Aug 18. Clin Lymphoma Myeloma Leuk. 2018. PMID: 30249389 Free PMC article. Clinical Trial.
First-line treatment of chronic lymphocytic leukemia with ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab: final analysis of the randomized, phase III iLLUMINATE trial.
Moreno C, Greil R, Demirkan F, Tedeschi A, Anz B, Larratt L, Simkovic M, Novak J, Strugov V, Gill D, Gribben JG, Kwei K, Dai S, Hsu E, Dean JP, Flinn IW. Moreno C, et al. Among authors: gill d. Haematologica. 2022 Sep 1;107(9):2108-2120. doi: 10.3324/haematol.2021.279012. Haematologica. 2022. PMID: 35021599 Free PMC article. Clinical Trial.
A randomized trial of high-versus conventional-dose cytarabine in consolidation chemotherapy for adult de novo acute myeloid leukemia in first remission after induction therapy containing high-dose cytarabine.
Bradstock KF, Matthews JP, Lowenthal RM, Baxter H, Catalano J, Brighton T, Gill D, Eliadis P, Joshua D, Cannell P, Schwarer AP, Durrant S, Gillett A, Koutts J, Taylor K, Bashford J, Arthur C, Enno A, Dunlop L, Szer J, Leahy M, Juneja S, Young GA; Australasian Leukaemia and Lymphoma Group. Bradstock KF, et al. Among authors: gill d. Blood. 2005 Jan 15;105(2):481-8. doi: 10.1182/blood-2004-01-0326. Epub 2004 Jun 22. Blood. 2005. PMID: 15213095 Free article. Clinical Trial.
Rare variants in Fanconi anemia genes are enriched in acute myeloid leukemia.
Maung KZY, Leo PJ, Bassal M, Casolari DA, Gray JX, Bray SC, Pederson S, Singhal D, Samaraweera SE, Nguyen T, Cildir G, Marshall M, Ewing A, Duncan EL, Brown MA, Saal R, Tergaonkar V, To LB, Marlton P, Gill D, Lewis I, Deans AJ, Brown AL, D'Andrea RJ, Gonda TJ. Maung KZY, et al. Among authors: d andrea rj, gill d. Blood Cancer J. 2018 Jun 1;8(6):50. doi: 10.1038/s41408-018-0090-7. Blood Cancer J. 2018. PMID: 29891941 Free PMC article. No abstract available.
A phase I/II study of intensive dose escalation of cytarabine in combination with idarubicin and etoposide in induction and consolidation treatment of adult acute myeloid leukemia. Australian Leukaemia Study Group (ALSG).
Lowenthal RM, Bradstock KF, Matthews JP, Bishop JF, Juneja S, Cobcroft R, Eliadis P, Enno A, Gill D, Herrmann RP, Manoharan A, Page FJ, Rooney KF, Rosenfeld D, Seldon M, Taylor KM, Wolf MM, Young GA. Lowenthal RM, et al. Among authors: gill d. Leuk Lymphoma. 1999 Aug;34(5-6):501-10. doi: 10.3109/10428199909058477. Leuk Lymphoma. 1999. PMID: 10492073 Clinical Trial.
Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): a multicentre, randomised, open-label, phase 3 trial.
Moreno C, Greil R, Demirkan F, Tedeschi A, Anz B, Larratt L, Simkovic M, Samoilova O, Novak J, Ben-Yehuda D, Strugov V, Gill D, Gribben JG, Hsu E, Lih CJ, Zhou C, Clow F, James DF, Styles L, Flinn IW. Moreno C, et al. Among authors: gill d. Lancet Oncol. 2019 Jan;20(1):43-56. doi: 10.1016/S1470-2045(18)30788-5. Epub 2018 Dec 3. Lancet Oncol. 2019. PMID: 30522969 Clinical Trial.
A cross-trial comparison of single-agent ibrutinib versus chlorambucil-obinutuzumab in previously untreated patients with chronic lymphocytic leukemia or small lymphocytic lymphoma.
Tedeschi A, Greil R, Demirkan F, Robak T, Moreno C, Barr PM, Anz B, Simpson D, Gaidano G, Bairey O, Stevens D, Gill D, Flinn IW, Kipps TJ, Burger JA, Lin J, Webb T, Fedorov V, Styles L, Gribben JG. Tedeschi A, et al. Among authors: gill d. Haematologica. 2020 Apr;105(4):e164-e168. doi: 10.3324/haematol.2019.223743. Epub 2019 Aug 14. Haematologica. 2020. PMID: 31413095 Free PMC article. Clinical Trial. No abstract available.
Effects of glycosylated recombinant human granulocyte colony-stimulating factor after high-dose cytarabine-based induction chemotherapy for adult acute myeloid leukaemia.
Bradstock K, Matthews J, Young G, Lowenthal R, Baxter H, Arthur C, Bashford J, Brighton T, Cannell P, Dunlop L, Durrant S, Enno A, Eliadis P, Gill D, Gillett A, Gottlieb D, Januszewicz H, Joshua D, Leahy M, Schwarer A, Taylor K; Australian Leukaemia Study Group. Bradstock K, et al. Among authors: gill d. Leukemia. 2001 Sep;15(9):1331-8. doi: 10.1038/sj.leu.2402218. Leukemia. 2001. PMID: 11516093 Clinical Trial.
The duality of macrophage function in chronic lymphocytic leukaemia.
Chen YCE, Mapp S, Blumenthal A, Burgess ML, Mazzieri R, Mattarollo SR, Mollee P, Gill D, Saunders NA. Chen YCE, et al. Among authors: gill d. Biochim Biophys Acta Rev Cancer. 2017 Aug;1868(1):176-182. doi: 10.1016/j.bbcan.2017.03.006. Epub 2017 Mar 24. Biochim Biophys Acta Rev Cancer. 2017. PMID: 28347751 Review.
A single-centre experience of post-renal transplant lymphoproliferative disorder.
Herzig KA, Juffs HG, Norris D, Brown AM, Gill D, Hawley CM, Cobcroft R, Petrie JB, Marlton P, Thomson D, Campbell SB, Nicol DL, Johnson DW. Herzig KA, et al. Among authors: gill d. Transpl Int. 2003 Jul;16(7):529-36. doi: 10.1007/s00147-003-0596-0. Epub 2003 May 7. Transpl Int. 2003. PMID: 12734646
Granulocyte-colony stimulating factor increases CD123hi blood dendritic cells with altered CD62L and CCR7 expression.
Vuckovic S, Kim M, Khalil D, Turtle CJ, Crosbie GV, Williams N, Brown L, Williams K, Kelly C, Stravos P, Rodwell R, Hill GR, Wright S, Taylor K, Gill D, Marlton P, Bradstock K, Hart DN. Vuckovic S, et al. Among authors: gill d. Blood. 2003 Mar 15;101(6):2314-7. doi: 10.1182/blood-2002-03-0973. Epub 2002 Oct 24. Blood. 2003. PMID: 12406901 Free article.
CD62L as a therapeutic target in chronic lymphocytic leukemia.
Burgess M, Gill D, Singhania R, Cheung C, Chambers L, Renyolds BA, Smith L, Mollee P, Saunders N, McMillan NA. Burgess M, et al. Among authors: gill d. Clin Cancer Res. 2013 Oct 15;19(20):5675-85. doi: 10.1158/1078-0432.CCR-13-1037. Epub 2013 Aug 15. Clin Cancer Res. 2013. PMID: 23948971
Pretreatment with ibrutinib reduces cytokine secretion and limits the risk of obinutuzumab-induced infusion-related reactions in patients with CLL: analysis from the iLLUMINATE study.
Greil R, Tedeschi A, Moreno C, Anz B, Larratt L, Simkovic M, Gill D, Gribben JG, Flinn IW, Wang Z, Cheung LWK, Nguyen AN, Zhou C, Styles L, Demirkan F. Greil R, et al. Among authors: gill d. Ann Hematol. 2021 Jul;100(7):1733-1742. doi: 10.1007/s00277-021-04536-6. Epub 2021 May 20. Ann Hematol. 2021. PMID: 34018029 Free PMC article. Clinical Trial.
Loss of PKR activity in chronic lymphocytic leukemia.
Hii SI, Hardy L, Crough T, Payne EJ, Grimmett K, Gill D, McMillan NA. Hii SI, et al. Among authors: gill d. Int J Cancer. 2004 Apr 10;109(3):329-35. doi: 10.1002/ijc.11714. Int J Cancer. 2004. PMID: 14961569
Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia.
Byrd JC, Brown JR, O'Brien S, Barrientos JC, Kay NE, Reddy NM, Coutre S, Tam CS, Mulligan SP, Jaeger U, Devereux S, Barr PM, Furman RR, Kipps TJ, Cymbalista F, Pocock C, Thornton P, Caligaris-Cappio F, Robak T, Delgado J, Schuster SJ, Montillo M, Schuh A, de Vos S, Gill D, Bloor A, Dearden C, Moreno C, Jones JJ, Chu AD, Fardis M, McGreivy J, Clow F, James DF, Hillmen P; RESONATE Investigators. Byrd JC, et al. Among authors: gill d. N Engl J Med. 2014 Jul 17;371(3):213-23. doi: 10.1056/NEJMoa1400376. Epub 2014 May 31. N Engl J Med. 2014. PMID: 24881631 Free PMC article. Clinical Trial.
Evaluating the Cardiometabolic Efficacy and Safety of Lipoprotein Lipase Pathway Targets in Combination With Approved Lipid-Lowering Targets: A Drug Target Mendelian Randomization Study.
Gagnon E, Gill D, Chabot D, Cronjé HT, Yuan S, Brennan S, Thériault S, Burgess S, Arsenault BJ, Dib MJ. Gagnon E, et al. Among authors: gill d. Circ Genom Precis Med. 2025 Mar 7:e004933. doi: 10.1161/CIRCGEN.124.004933. Online ahead of print. Circ Genom Precis Med. 2025. PMID: 40052268
Intervention, improved prevention, imaging, inflammation, and innovation: the five I's cardiovascular highlights in EHJ Open 2024.
Bäck M, Banach M, Braunschweig F, De Rosa S, Flachskampf FA, Kahan T, Ketelhuth DFJ, Lancellotti P, Larsson SC, Mellbin L, Savarese G, Jensen AS, Szummer K, Wahl D; European Heart Journal Open Section Editors. Bäck M, et al. Eur Heart J Open. 2025 Feb 28;5(1):oeaf015. doi: 10.1093/ehjopen/oeaf015. eCollection 2025 Jan. Eur Heart J Open. 2025. PMID: 40041611 Free PMC article. No abstract available.
Genomics-Informed Drug Repurposing Strategy Identifies Novel Therapeutic Targets for Metabolic Dysfunction-Associated Steatotic Liver Disease.
Seagle HM, Akerele AT, DeCorte JA, Hellwege JN, Breeyear JH, Kim J, Levin M, Khodurksy S, Bress A, Lee K, Meiler J, Gill D, Lee JS, Heberer K, Miller DR, Reaven P, Chang KM, Lynch JA, Khankari NK, Shuey MM, Edwards TL, Vujkovic M. Seagle HM, et al. Among authors: gill d. medRxiv [Preprint]. 2025 Feb 21:2025.02.18.25321035. doi: 10.1101/2025.02.18.25321035. medRxiv. 2025. PMID: 40034783 Free PMC article. Preprint.
Cross-Ancestry Comparison of Aptamer and Antibody Proteomics Measures.
Nicholas JC, Katz DH, Tahir UA, Debban CL, Aguet F, Blackwell T, Bowler RP, Broadaway KA, Chen J, Clish CB, Coresh J, Cornell E, Cruz DE, Deo R, Doyle MF, Durda P, Ekunwe L, Floyd JS, Gill D, Guo X, Hoogeveen RC, Johnson C, Lange LA, Li Y, Manning A, Meigs JB, Mi MY, Mychaleckyj JC, Olson NC, Pratte KA, Psaty BM, Reiner AP, Ruan P, Sevilla-Gonzalez M, Shah AM, Sun Q, Tracy RP, Wen J, Wood AC, Wilson JG, Young KL, Yu B, Rooney MR, Manichaikul A, Dubin R, Mohlke KL, Rich SS, Rotter JI, Ganz P, Gerszten RE, Taylor KD, Raffield LM. Nicholas JC, et al. Among authors: gill d. Res Sq [Preprint]. 2025 Feb 13:rs.3.rs-5968391. doi: 10.21203/rs.3.rs-5968391/v1. Res Sq. 2025. PMID: 39989965 Free PMC article. Preprint.
A sustainable ocean needs thriving ocean societies.
Claudet J, Blythe J, Gill D. Claudet J, et al. Among authors: gill d. Nature. 2025 Feb;638(8051):614. doi: 10.1038/d41586-025-00494-5. Nature. 2025. PMID: 39966634 No abstract available.
Health Insurance Coverage Among Adolescent and Young Adult Cancer Survivors Receiving Health Care before and During the COVID-19 Pandemic.
Rogers KN, Kaddas HK, Ramsay JM, Waters AR, Vaca Lopez PL, van Thiel Berghuijs K, Linder L, Lewis MA, Warner EL, Gill D, Kirchhoff AC. Rogers KN, et al. Among authors: gill d. J Adolesc Young Adult Oncol. 2025 Feb 10. doi: 10.1089/jayao.2024.0115. Online ahead of print. J Adolesc Young Adult Oncol. 2025. PMID: 39927401
Genetically Predicted IL-18 Inhibition and Risk of Cardiovascular Events: A Mendelian Randomization Study.
Brennan SO, Kelly PJ, Gorey S, Synnott P, Gill D, Dichgans M, Georgakis MK, Dib MJ, Gagnon E, Mahon N, Blake GJ, Jern C, Markus HS, Whiteley W, McCabe JJ. Brennan SO, et al. Among authors: gill d. Circulation. 2025 Feb 4;151(5):334-336. doi: 10.1161/CIRCULATIONAHA.124.072238. Epub 2025 Feb 3. Circulation. 2025. PMID: 39899632 No abstract available.
Management of Patients with Myocardial Injury After Noncardiac Surgery: A Retrospective Chart Review.
Wang MK, Sabac D, Sadhak R, Ajay A, Benayon M, Borges FK, Cha Y, Conen D, Coomber M, Fuller K, Gill D, Jayachandiran R, Koubaesh C, Latchupatula L, Moosa S, Ofori S, Pasumarthi K, Patel A, Samari S, Blum S, Suresh M, Tandon V, Devereaux PJ, Marcucci M. Wang MK, et al. Among authors: gill d. CJC Open. 2024 Oct 11;7(1):103-109. doi: 10.1016/j.cjco.2024.10.004. eCollection 2025 Jan. CJC Open. 2024. PMID: 39872652 Free PMC article.
The effects of ultra-selective beta1-antagonism on the metabolic and cytokine profile in septic shock patients receiving noradrenaline: a sub-investigation from the STRESS-L Randomised Study.
Thomas JL, McGee KC, Hossain A, Perkins GD, Gordon AC, Young D, McAuley D, Singer M, Lall R, Kramaric T, Lord JM, Whitehouse T, Mur LAJ; STRESS-L. collaborators. Thomas JL, et al. Intensive Care Med Exp. 2025 Jan 22;13(1):9. doi: 10.1186/s40635-024-00708-6. Intensive Care Med Exp. 2025. PMID: 39841388 Free PMC article.
Conservation benefits of a large marine protected area network that spans multiple ecosystems.
Smith JG, Lopazanski C, Free CM, Brun J, Anderson C, Carr MH, Claudet J, Dugan JE, Eurich JG, Francis TB, Gill DA, Hamilton SL, Kaschner K, Mouillot D, Raimondi PT, Starr RM, Ziegler SL, Malone D, Marraffini ML, Parsons-Field A, Spiecker B, Yeager M, Nickols KJ, Caselle JE. Smith JG, et al. Among authors: gill da. Conserv Biol. 2025 Jan 9:e14435. doi: 10.1111/cobi.14435. Online ahead of print. Conserv Biol. 2025. PMID: 39786314
Shared governance increases marine protected area effectiveness.
Mast A, Gill D, Ahmadia GN, Darling ES, Andradi-Brown DA, Geldman J, Epstein G, MacNeil MA. Mast A, et al. Among authors: gill d. PLoS One. 2025 Jan 8;20(1):e0315896. doi: 10.1371/journal.pone.0315896. eCollection 2025. PLoS One. 2025. PMID: 39775317 Free PMC article.
Opioid use disorder and brain health: observational and genetic associations.
Javidnia S, Roe JM, Karhunen V, Gill D, Bell S, Deak J, Levey D, Cronje T, Burgess S, Gelernter J, Ebmeier KP, Topiwala A. Javidnia S, et al. Among authors: gill d. medRxiv [Preprint]. 2024 Dec 18:2024.12.18.24319222. doi: 10.1101/2024.12.18.24319222. medRxiv. 2024. PMID: 39763526 Free PMC article. Preprint.
Proteomic changes upon treatment with semaglutide in individuals with obesity.
Maretty L, Gill D, Simonsen L, Soh K, Zagkos L, Galanakis M, Sibbesen J, Iglesias MT, Secher A, Valkenborg D, Purnell JQ, Knudsen LB, Tahrani AA, Geybels M. Maretty L, et al. Among authors: gill d. Nat Med. 2025 Jan;31(1):267-277. doi: 10.1038/s41591-024-03355-2. Epub 2025 Jan 3. Nat Med. 2025. PMID: 39753963 Free PMC article. Clinical Trial.
1,948 results